Real-World look at myelofibrosis Drug's impact on spleen size
NCT ID NCT07249606
Summary
This study aims to observe how well the drug momelotinib works for people with myelofibrosis in everyday medical practice. It will follow 93 adults with the condition who are already taking the drug as part of their standard care. The main goal is to see if the treatment reduces the size of an enlarged spleen by at least half after six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.